Related Experiment Videos
Six-month combination chemotherapy for cervical tuberculous lymphadenitis
1Department of Surgery, University of Hong Kong, Queen Mary Hospital.
Journal of the Royal College of Surgeons of Edinburgh
|October 1, 1990
Summary
Six months of a four-drug regimen effectively treated cervical tuberculous lymphadenitis in most patients. While some experienced minor side effects or residual lymph nodes, recurrence was low, indicating this chemotherapy duration is adequate.
Area of Science:
- Infectious Diseases
- Oncology
- Pulmonology
Background:
- Cervical tuberculous lymphadenitis is a significant global health challenge.
- Optimal treatment duration for this condition remains a subject of research.
Purpose of the Study:
- To evaluate the efficacy of a 6-month four-drug regimen for cervical tuberculous lymphadenitis.
- To assess long-term outcomes, including recurrence and residual disease, at 3-year follow-up.
Main Methods:
- A prospective study involving 123 patients with cervical tuberculous lymphadenitis.
- Treatment with a 6-month four-drug combination chemotherapy regimen.
- Follow-up for 3 years to monitor disease control and recurrence.
Main Results:
- The 6-month regimen achieved satisfactory disease control in most patients, with 14.6% showing no need for further chemotherapy at 3 years.
- Recurrence requiring additional chemotherapy occurred in 3.3% of patients.
- Excisional procedures were linked to fewer residual lymph nodes compared to incisional biopsies.
Conclusions:
- Six months of combination chemotherapy is sufficient for treating cervical tuberculous lymphadenitis.
- The study highlights the effectiveness of the regimen with a low recurrence rate and manageable side effects.